Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Department of Biophysics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Indian J Pharmacol. 2020 Jan-Feb;52(1):56-65. doi: 10.4103/ijp.IJP_115_20. Epub 2020 Mar 11.
The 2019-novel coronavirus (nCoV) is a major source of disaster in the 21 century. However, the lack of specific drugs to prevent/treat an attack is a major need at this current point of time. In this regard, we conducted a systematic review to identify major druggable targets in coronavirus (CoV). We searched PubMed and RCSB database with keywords HCoV, NCoV, corona virus, SERS-CoV, MERS-CoV, 2019-nCoV, crystal structure, X-ray crystallography structure, NMR structure, target, and drug target till Feb 3, 2020. The search identified seven major targets (spike protein, envelop protein, membrane protein, protease, nucleocapsid protein, hemagglutinin esterase, and helicase) for which drug design can be considered. There are other 16 nonstructural proteins (NSPs), which can also be considered from the drug design perspective. The major structural proteins and NSPs may serve an important role from drug design perspectives. However, the occurrence of frequent recombination events is a major deterrent factor toward the development of CoV-specific vaccines/drugs.
2019 年新型冠状病毒(nCoV)是 21 世纪的主要灾害源。然而,目前缺乏预防/治疗攻击的特定药物是一个主要需求。在这方面,我们进行了系统评价,以确定冠状病毒(CoV)中的主要可成药靶标。我们使用关键字 HCoV、NCoV、冠状病毒、SERS-CoV、MERS-CoV、2019-nCoV、晶体结构、X 射线晶体学结构、NMR 结构、靶标和药物靶标在 2020 年 2 月 3 日之前在 PubMed 和 RCSB 数据库中进行了搜索。搜索确定了七个主要靶标(刺突蛋白、包膜蛋白、膜蛋白、蛋白酶、核衣壳蛋白、血凝素酯酶和螺旋酶),可以考虑用于药物设计。还有其他 16 种非结构蛋白(NSPs),也可以从药物设计的角度来考虑。主要结构蛋白和 NSPs 可能从药物设计的角度来看具有重要作用。然而,频繁发生的重组事件是开发 CoV 特异性疫苗/药物的主要障碍因素。